Tag: Palantir

Weekly Update

Weekly Market Overview – October 5–October 11, 2026

Palantir becomes the largest UMBRELLA position. SpaceX gains, Dell is added, and Bayer exits. The focus on AI and technology
Continue Umbrella
Weekly Update

Weekly Market Overview – August 3-August 9, 2026

Palantir impresses with strong growth. The UMBRELLA strategy also focuses on healthcare, European defense, and structural trends.
Continue Umbrella
Weekly Update

Weekly Market Overview – August 17-August 23, 2026

Healthcare and AI provided support in a mixed week, while European defense stocks and SpaceX were more under pressure. There
Continue Umbrella
Weekly Update

Weekly Market Overview – August 24–August 30, 2026

Revolution Medicines reaches a major milestone with the FDA approval of RASONQUE, while PayPal saw significant price fluctuations following the
Continue Umbrella
Weekly Update

Weekly Market Overview – August 10-August 16, 2026

TKMS raises its outlook, SpaceX is added to the UMBRELLA strategy, thereby strengthening its focus on defense, AI, and the
Continue Umbrella
Weekly Update

Weekly Market Overview – May 25–31, 2026

The UMBRELLA Strategy is placing a stronger emphasis on AI, technology, healthcare, and defense. Tesla remains the largest single position.
Continue Umbrella
Palantir
Technology
USA

Valuation Analysis: Palantir Technologies

Palantir rapidly increases revenue, margins, and cash flow. The analysis highlights AI opportunities, defense business, and valuation risks.
Active icon
Continue Umbrella
Palantir
Technology
USA

Stock: Palantir Technologies

Palantir impressed in Q2 2026 with strong growth, record margins, and a technical breakout.
Active icon
Continue Umbrella
MUMAK SpotLight

MUMAK SpotLight of the week: Five stocks in focus

Eli Lilly, Rheinmetall, Bayer, Palantir, and Revolution Medicines impress with strong developments—but valuation, risks, and chart technicals remain decisive.
Continue Umbrella
Palantir
Company Update

Palantir Update: What’s behind the volatility?

Following the strong August rally, Palantir is seeing pronounced price swings. Strong growth meets a high valuation and elevated market
Continue Umbrella
MUMAK SpotLight

MUMAK SpotLight of the week: Revolution Medicines with FDA breakthrough. PayPal and Palantir in focus

Revolution Medicines reaches a decisive milestone with the FDA approval of Daraxonrasib. PayPal loses a key short-term price driver as
Continue Umbrella
MUMAK SpotLight

MUMAK SpotLight of the week: Intel becomes part of the UMBRELLA Strategy

Intel was newly added to the UMBRELLA Strategy, expanding the portfolio's semiconductor positioning. At the same time, Revolution Medicines, Bayer,
Continue Umbrella